ResMed Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B | $3.20B | $2.96B | $2.61B |
| Cost of Revenue | $2.20B | $2.09B | $2.03B | $1.87B | $1.55B | $1.36B | $1.24B | $1.11B |
| Gross Profit | $3.45B | $3.05B | $2.66B | $2.36B | $2.02B | $1.84B | $1.72B | $1.49B |
| Gross Margin | 61.1% | 59.4% | 56.7% | 55.8% | 56.6% | 57.5% | 58.1% | 57.3% |
| Operating Expenses | ||||||||
| Research & Development | $378.3M | $331.3M | $307.5M | $287.6M | $253.6M | $225.3M | $201.9M | $180.7M |
| SG&A Expense | $1.12B | $993.1M | $917.1M | $874.0M | $737.5M | $670.4M | $676.7M | $645.0M |
| Operating Income | $1.89B | $1.69B | $1.32B | $1.13B | $1.00B | $903.7M | $809.7M | $579.3M |
| Operating Margin | 33.4% | 32.7% | 28.2% | 26.8% | 28.0% | 28.3% | 27.4% | 22.2% |
| Interest Expense | — | — | — | — | — | $24.0M | $40.4M | $36.2M |
| Pretax Income | $1.92B | $1.68B | $1.26B | $1.10B | $960.5M | $883.7M | $733.1M | $518.8M |
| Income Tax Expense | $396.1M | $276.8M | $243.8M | $204.1M | $181.0M | $409.2M | $111.4M | $114.3M |
| Net Income | $1.52B | $1.40B | $1.02B | $897.6M | $779.4M | $474.5M | $621.7M | $404.6M |
| Net Margin | 26.9% | 27.2% | 21.8% | 21.3% | 21.8% | 14.8% | 21.0% | 15.5% |
| EPS (Basic) | $10.47 | $9.55 | $6.94 | $6.12 | $5.34 | $3.27 | $4.31 | $2.83 |
| EPS (Diluted) | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 | $2.80 |
| Shares Outstanding (Basic) | 145.5M | 146.7M | 147.0M | 146.8M | 146.1M | 145.3M | 144.3M | 143.1M |
| Shares Outstanding (Diluted) | 146.1M | 147.3M | 147.6M | 147.5M | 147.0M | 146.5M | 145.7M | 144.5M |
| Dividends Per Share | $2.40 | $2.12 | $1.92 | $1.76 | $1.68 | $1.56 | $1.56 | $1.48 |